- Home
- EQX vs RCKT Comparison
EQX vs RCKT Comparison
Compare EQX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQX | RCKT |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 394.2M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | EQX | RCKT |
|---|---|---|
| Price | $10.85 | $2.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $8.85 |
| AVG Volume (30 Days) | ★ 10.9M | 1.6M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.47% | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | N/A | ★ 0.66 |
| Revenue | N/A | N/A |
| Revenue This Year | $125.84 | N/A |
| Revenue Next Year | $31.12 | $915.60 |
| P/E Ratio | $137.41 | ★ $3.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.49 | $2.51 |
| 52 Week High | $18.96 | $5.45 |
Technical Indicators
Market Signals| Indicator | EQX | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 40.29 | 28.87 |
| Support Level | $9.34 | N/A |
| Resistance Level | $12.05 | $3.67 |
| Average True Range (ATR) | 0.42 | 0.21 |
| MACD | -0.19 | -0.09 |
| Stochastic Oscillator | 0.26 | 7.23 |
Price Performance
Historical ComparisonAbout EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. The company operates gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the Canada, United States, Mexico, and others. The majority of its revenue is generated from Canada.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.